RxDoctor Payments Data

Jacob Menard

Nurse Practitioner · de Pere, WINPI 1386360139

Payments from drug & device makers

$2,163in general payments, 2019–2025

Across 95 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$321
  • Johnson & Johnson$231
  • Sumitomo Pharma America, Inc.$218
  • Urogen Pharma, Inc.$206
  • Teleflex LLC$167
  • Olympus America Inc.$153
  • plus $867 from 19 others

What the payments were for

  • Food & beverage$1,92989%
  • Education$23411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,163 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$16,064
Medicare patients
136
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$38,591
Abiraterone Acetate16$22,642
GemtesaVibegron12$10,415
Tamsulosin Hcl197$1,919
Trospium Chloride ErTrospium Chloride16$1,752
Trospium Chloride32$1,329
Potassium Citrate ErPotassium Citrate11$613
Finasteride48$528
Oxybutynin Chloride16$466
Cephalexin39$193
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$143
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$126
Ciprofloxacin Hcl16$71
Levofloxacin31$44
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$144$38,59152 claims
Sumitomo Pharma America, Inc.Gemtesa$218$10,41512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in de Pere

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →